Comparison of combination chemotherapy plus IFN-α and combination chemotherapy and Rituximab (a monoclonal antibody also licensed for Follicular Lymphoma) is the subject of an ongoing clinical trial. The gene discussed is IFNA2; the disease is follicular lymphoma.